X-rays Actuate Anticancer Drugs: Opening New Vistas in Prodrug Therapy

Shreyas P. Vaidya, Malay Patra*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Chemotherapy is the primary treatment modality employed in the clinic for the treatment of cancer. Despite proven clinical success, adverse side effects are one of the drawbacks of this approach. The prodrug strategy has emerged as an alternative approach with the aim of alleviating these drawbacks. Prodrug activation is typically achieved by either endogenous or exogenous triggers. Exogenous triggers like light are appealing as they are independent of inherent patient and/or cancer-type variations. However, tissue penetration depth remains the Achilles’ heel of this approach. In this context, usage of X-rays as the external trigger with infinite tissue penetration depth opens up exciting prospects in prodrug activation strategies.

Original languageEnglish
Pages (from-to)2998-3000
Number of pages3
Issue number21
StatePublished - 3 Nov 2021
Externally publishedYes


  • X-ray
  • chemotherapy
  • doxorubicin
  • light
  • medicinal chemistry
  • prodrug


Dive into the research topics of 'X-rays Actuate Anticancer Drugs: Opening New Vistas in Prodrug Therapy'. Together they form a unique fingerprint.

Cite this